AGMB — Agomab Therapeutics NV
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2020932 ·
Belgium
Last close
$12.87
Market Cap
$633.82M
52W High
$17.82
52W Low
$8.75
ADV30
95,840
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -16,527,000 | -17,401,000 | 153,706,000 | 86,418,000 | 22,804,000 |
| Sep 2025 | — | — | — | — | 165,631,000 | 129,585,000 | 18,700,000 |
| Dec 2024 | 0 | — | -11,814,000 | -11,732,000 | 206,358,000 | 171,459,000 | 18,277,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,609,000
Investing CF
$-30,367,000
Financing CF
$81,829,000
CapEx
$-363,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-181,714,000
Inventory
—
Receivables
$4,085,000
ST Investments
$30,096,000
EBIT TTM
$-29,423,000
Pretax Income TTM
$-29,129,000
Interest Exp TTM
$-294,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,275,000 | -62,547,000 | 153,706,000 | 22,804,000 | — | -51,741,000 |
| Dec 2024 | 0 | -48,021,000 | -46,267,000 | 206,358,000 | 18,277,000 | — | -46,828,000 |
| Dec 2023 | 0 | -31,190,000 | -11,390,000 | 171,259,000 | 19,824,000 | — | -24,592,000 |
| Dec 2022 | 0 | -22,634,000 | -8,142,000 | 100,995,000 | 34,747,000 | — | -18,967,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $620.36M | $9.69 | — |
| ALLO | Allogene Therapeutics, Inc. | $648.89M | $1.88 | — |
| AURA | Aura Biosciences, Inc. | $725.09M | $7.01 | — |
| CADL | Candel Therapeutics, Inc. | $733.44M | $10.01 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $532.17M | $10.18 | — |
News headlines (Yahoo Finance, 1h cache)
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
2026-07-02 20:06 · Yahoo
Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease
2026-06-23 21:32 · Yahoo
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
2026-06-23 20:05 · Yahoo
Agomab to Participate in Upcoming Conferences
2026-05-14 11:30 · Yahoo
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
2026-04-23 22:14 · Yahoo
AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
2026-04-12 18:46 · Yahoo
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
2026-03-26 11:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Higher Wednesday
2026-02-18 16:15 · Yahoo
Agomab Announces Closing of Initial Public Offering
2026-02-09 21:05 · Yahoo
Agomab indicated to open at $15.50, IPO priced at $16
2026-02-07 15:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.